Historial de carrera de Matthew J. Pietras
Antiguos cargos conocidos de Matthew J. Pietras.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
STAGEZERO LIFE SCIENCES LTD. | Director de Operaciones | 28/08/2021 | 26/05/2022 |
Director Financiero/CFO | 28/08/2021 | 26/05/2022 | |
VIELA BIO, INC. | Comptroller/Controller/Auditor | 01/01/2017 | 01/01/2019 |
Treasurer | 01/01/2017 | 01/01/2019 | |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Director Financiero/CFO | - | - |
Formación de Matthew J. Pietras.
The Johns Hopkins University | Masters Business Admin |
The Pennsylvania State University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Canadá | 2 |
Operativa
Director of Finance/CFO | 2 |
Chief Operating Officer | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
STAGEZERO LIFE SCIENCES LTD. | Health Technology |
Empresas privadas | 2 |
---|---|
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Health Technology |
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
- Bolsa de valores
- Insiders
- Matthew J. Pietras
- Experiencia